Management Board

Biography

Dr. Christian Wojczewski (born in 1971, German citizen) joined Evotec as Chief Executive Officer and Chairman of the Management Board on 01 July 2024. Dr. Wojczewski has over 20 years of experience in various top management positions, most recently at Mediq and Linde Healthcare. He is an experienced CEO with a proven track record in building and leading large, high-performing life science organisations, and with deep strategic, operational and transformational expertise. Dr. Wojczewski holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe-University in Frankfurt am Main. He worked as a manager at McKinsey for companies in the life science and chemical industries in Europe and the USA. In 2005, he joined Linde, the global market leader for medical and industrial gases. After various roles within the company, Dr. Wojczewski took over as Head of Group Strategy and later additionally assumed leadership of Linde Healthcare, one of the Group’s key growth businesses. During his tenure, Linde Healthcare developed into the global market leader for medical gases and services for patients with chronic respiratory diseases operating in more than 60 countries. In 2017, Dr. Wojczewski joined Mediq in the Netherlands, a European leader in medical devices and related services, as group CEO. Under Dr. Wojczewski’s leadership, Mediq achieved an impressive turnaround with strong EBITDA recovery and towards profitable growth

Biography

Claire Hinshelwood (British citizen) joined Evotec as Chief Financial Officer and Member of the Management Board effective May 1, 2026. She brings more than 30 years of international experience in senior financial leadership roles across complex, global organizations, with a strong track record in financial stewardship, transformation and operational effectiveness.

Most recently, Ms. Hinshelwood served as Group Chief Financial Officer of BMI Group, where she led the company’s finance function and supported the transformation of financial operations during a period of challenging market conditions. In this role, she focused on strengthening financial governance, performance management and organizational resilience.

Prior to this, Ms. Hinshelwood held senior global leadership roles at Novartis, including Global Head of Finance Operations, where she was responsible for finance operations across multiple regions and functions. Earlier in her career, she spent 15 years at Syngenta in a range of international finance leadership positions, including Head of Business Services for Latin America and Head of Finance for Eastern Europe and Asia‑Pacific. Across these roles, she gained extensive experience in managing finance organizations in highly international, matrix‑driven environments and supporting business transformation initiatives.

Ms. Hinshelwood began her professional career in finance controller roles in the consumer goods sector, building a strong foundation in financial management, reporting and control.

She holds a Bachelor’s degree in Accountancy and Finance from Heriot‑Watt University in Edinburgh, Scotland and is a member of the Chartered Institute of Management Accountants (CIMA). Ms. Hinshelwood has extensive international experience across Europe, Latin America and Asia‑Pacific and brings a global perspective to financial leadership.

Biography 

Dr. Cord Dohrmann (born in 1964, German citizen) joined Evotec as Chief Scientific Officer and Member of the Management Board in 2010. Dr. Dohrmann has spent over 25 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the Max Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining a Max Planck Institute spin-off company, DeveloGen, in 1999. During his ten-year tenure, he served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company. Dr. Cord Dohrmann is a member of the Supervisory Boards of Eternygen and Breakpoint Therapeutics, a Non-Executive Member of the Board of Directors of Facio Therapies and a Board Observer of Immunitas Inc. He has been advising the European Commission, the Max Planck Institute as well as various venture capital firms. In February 2021, Dr. Dohrmann was appointed to the German Council of Science and Humanities.

Biography

Dr. Ingrid Müller (born in 1972, German citizen) joined Evotec as Chief Operating Officer and Member of the Management Board effective May 1, 2026. She brings more than 20 years of international leadership experience in the life sciences industry, spanning operations, strategy, supply chain, procurement and R&D integration. In her role, Dr Müller is responsible for Evotec’s D&PD operations and supports cross‑functional execution across the organization.

Most recently, Dr. Müller served as Vice President Portfolio Strategy & Execution at CureVac N.V. In this role, she focused on corporate and portfolio strategy, supporting the alignment of research and development activities with long‑term business objectives.

Prior to CureVac, Dr. Müller held several senior international leadership roles at Sanofi, including Senior Vice President Global Procurement, External Manufacturing & Operations and Vice President Global Supply Chain Diabetes and as Head PMO & Governance in Biologics. In these positions, she led global teams across operations and supply functions and contributed to strengthening operational resilience, advancing transformation initiatives and managing complex international manufacturing and sourcing environments. 

Dr. Müller began her professional career at Fresenius Kabi, where she worked as Director Innovation & Project Portfolio Management Pharmaceuticals and as Clinical Project Manager in innovation and global portfolio roles, contributing to international product launches, life‑cycle management and geographic expansion initiatives.

Dr. Müller holds a doctorate in natural sciences and a diploma in Biochemistry from Johann Wolfgang Goethe University in Frankfurt am Main. She has completed executive education at INSEAD and other leading business schools. Dr. Müller has extensive international experience across Europe, the Americas and Asia and speaks German and Spanish as native languages, with full professional proficiency in English and French.

Biography 

Aurélie Dalbiez (born in 1977, French citizen) joined Evotec as Chief People Officer and Member of the Management Board on 15 June 2024. In her role as CPO, Aurélie oversees the development and implementation of Evotec’s people strategy, focusing on fostering a culture of innovation, collaboration, and belonging. With over 25 years of international people leadership experience, Aurélie has a wealth of experience and expertise in Human Resources and a proven track record of driving organizational transformation and fostering employee engagement.

Prior to joining Evotec, Aurélie served as the Chief Human Resources Officer (“CHRO”) at Corbion N.V., a global bio-based ingredients company headquartered in Amsterdam, Netherlands. Previously, she was Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career in the banking industry, first at Deutsche Bank and later at Capital Group.

Aurélie brings a multi-cultural background and perspective. She lived in the United States, earned her university degree in International Business in Lyon, France and worked internationally throughout her career, mainly in Switzerland and The Netherlands with assignments in Spain, Germany, and France. She is fluent in French and English and also speaks German and Spanish.